Latest California Healthline Stories
Drugmakers Dramatically Boosted Lobbying Spending In Trump’s First Quarter
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
GOP Conservatives’ Goal To Relax Mandatory Health Benefits Unlikely To Tame Premiums
The federal health law requires most insurance plans to offer 10 specific categories of essential benefits. Conservatives would like to get rid of that rule in the hopes of bringing down premium costs.
Hospital Ratings Sites Give Consumers Something To Go On
Nearly half of state hospitals received a grade of C or lower for patient safety on a report card aimed at prodding them to do more to prevent injuries and deaths.
Stalking The ‘Unknown Enemy’: Doctors Scope Out Rare Diseases
An NIH-funded network of hospitals uses advanced genetic science and nationwide collaboration to diagnose rare and sometimes undiscovered diseases.
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump’s Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Readers: Training Patients To Advocate For Their Illnesses Is ‘A Virtue Not A Sin’
Readers react to and comment on recent stories.
California Hospitals Lose Ground In Quality Of Care, Report Card Shows
The nonprofit Leapfrog Group shows nearly half of California hospitals got a grade of C, D or F in patient safety measures — an increase from two years ago.
Grasping For The Middle Ground On Obamacare
A University of Southern California professor says conservatives and liberals should split the difference: Scrap the exchanges and expand Medicaid.
In Idaho, Tiny Facility Lights Way For Stressed Rural Hospitals
In a region where bears outnumber people, a small medical facility sets a modern example for hospitals on life support.
California Presses Forward In Fight To Regulate Pharma
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.